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Definition 
  
• Hepatitis is a disease or clinical syndrome in other 
diseases defined by the inflammation of the 
liver with the presence of inflammatory cells in 
its tissues and may occur with limited or no 
symptoms, but often leads to jaundice , poor 
appetite, and malaise 
• Hepatitis is chronic when it persists longer than 
six months 
• Chronic hepatitis may progress over time 
to fibrosis and cirrhosis (chronic liver failure)   
 
 en.wikipedia.org/wiki/Hepatitis 
Classification 
  • Viral hepatitis  - B, C, D (requires hepatitis B to cause disease). 
• Alcoholic hepatitis (alcohol intake in excess of 80 grams of 
alcohol a day in men and 40 grams a day in women is 
associated with development of alcoholic hepatitis). 
• Toxic and drug-induced (a large number of medications and 
other chemical agents can cause hepatitis: acetaminophen, 
antibiotics, and central nervous system medications) hepatitis. 
• Autoimmune (lupoid) hepatitis (caused by an abnormal 
immune response against liver cells, very often as clinical 
syndrome in other autoimmune diseases). 
• Non-alcoholic fatty liver.  
• Ischemic hepatitis (shock liver, is most often associated 
with heart failure). 
• Wilson Disease. 
 en.wikipedia.org/wiki/Hepatitis 
 Epidemiology 
  
• Hepatitis B is the most common viral hepatitis 
worldwide, affecting as much as 10% of the adult 
population in endemic areas and causing 
approximately 780,000 deaths per year worldwide. 
• Hepatitis C affects an estimated 3.2 million adults living 
in the United States and roughly 60-70% of HCV-
infected adults  are unaware of their infection.  
• Autoimmune hepatitis has an incidence of 1-2 per 
100,000 per year, and a prevalence of 10-20/100,000 
and affects women much more often than men (70%).  
 
 en.wikipedia.org/wiki/Hepatitis 
 Epidemiology 
  
The global prevalence of hepatitis B is not static, either. 
Southeast Asia and sub-Saharan Africa have the highest 
prevalences.  
medscape.org/viewarticle/510444 
 Epidemiology 
  
slideshare.net/MarioMondelli/viral-hepatitis-2013 
Etiology 
  
• Viral hepatitis is the most common cause of chronic hepatitis (B, C, D) and is 
a systemic viral infection that predominantly involves the liver.  
• Other common causes of non-viral hepatitis include toxic (notably alcohol, 
some industrial organic solvents, and plants) and drug-induced (such as 
paracetamol), alcoholic, autoimmune, fatty liver, and metabolic disorders 
(autosomal recessive inherited disorder of copper metabolism  - Wilson 
Disease) 
• Less commonly some bacterial, parasitic, fungal, mycobacterial and 
protozoal infections can cause hepatitis 
• Additionally, certain complications of pregnancy and decreased blood 
flow to the liver can induce hepatitis 
• Cholestasis (obstruction of bile flow) due to hepatocellular 
dysfunction, biliary tract obstruction, or biliary atresia can result in liver 
damage and hepatitis.   
 en.wikipedia.org/wiki/Hepatitis 
Etiology 
Hepatitis B Particle Types 
  
• The hepatitis B virion (HBV, the Dane particle) has a diameter around 42nm 
• The outer envelope contains high amounts of hepatitis B surface proteins 
• The envelope surrounds the inner nucelocapsid which is comprised of 180 hepatitis B core proteins 
arranged in an icosahedral arrangement with T=3 and T=4 symmetry 
• The nucleocapsid also contains at least one hepatitis B polymerase protein as well as the HBV genome  
• Two other subviral particles can be found in an infected individual's serum, namely the hepatitis B filament 
and hepatitis B sphere (a diameter of 22nm) that are composed solely of hepatitis B surface proteins 
without infectious nature  
http://www.hepatitisbviruspage.com/hbvparts.htm 
Etiology 
Hepatitis C Particle Types 
  
• The hepatitis C virus (HCV) particle consists of a 
core of genetic material (RNA), surrounded by 
an icosahedral protective shell of protein, and 
further encased in a lipid (fatty) envelope of 
cellular origin 
• Two viral envelope glycoproteins, E1 and E2, are 
embedded in the lipid envelope 
• The virus replicates mainly in the hepatocytes of 
the liver, where it is estimated that daily each 
infected cell produces approximately fifty virions 
with a calculated total of one trillion virions 
generated 
• The virus may also replicate in peripheral blood 
mononuclear cells, potentially accounting for the 
high levels of immunological disorders found in 
chronically infected HCV patients 
http://www.hepatitisbviruspage.com/hbvparts.htm 
Etiology 
Hepatitis D Particle Types 
  
• In 1977, an Italian doctor named Mario Rizzetto discovered a new nuclear antigen in the liver cells of 
patients infected with Hepatitis B Virus (HBV) 
• The antigen was thought to be a new protein encoded by HBV, and it was labeled as the delta antigen 
• Subsequent research on chimpanzees, however, indicated that this antigen was derived from a new virus, 
named the Hepatitis Delta Virus (HDV) 
• HDV is not classified into a viral family because it is a unique virus dependent on HBV 
http://web.stanford.edu/group/virus/delta/2005/ 
Etiology 
Hepatitis viruses 
  
https://en.wikipedia.org/wiki/Viral_hepatitis 
  HAV HBV HCV HDV HEV 
Transmission Enteral Parenteral Parenteral Parenteral Enteral 
Classification Picornavirus Orthohepadnavirus Hepacivirus Deltavirus Hepevirus 
Genome +ssRNA dsDNA-RT +ssRNA −ssRNA +ssRNA 
Antigens HBsAg,HBeAg Core antigen Delta antigen 
Incubation period 20–40 days 45–160 days 15–150 days 30–60 days 15–60 days 
Severity/Chronicity mild; acute 
occasionally 
severe; 5–10% 
chronic 
subclinical; 70% 
chronic 
exacerbates 
symptoms of 
HBV; chronic 
w/ HBV 
normal patients, 
mild; pregnant 
women, severe; 
acute 
Vaccine 
10 year 
protection 
3 injections, 
lifetime protection 
None available 
None 
available 
Investigational 
(approved in 
China) 
Etiology 
Chronic viral hepatitis 
• Hepatitis B transmitted vertically in areas of high 
incidence (perinatally) from mother to baby 
during birth) or horizontally by being exposed to 
infected blood or blood products or less common 
through exposure to mucous membranes  
• Hepatitis C  transmitted in same ways and has 
become the most common viral hepatitis since 
widespread vaccination for Hepatitis B in the mid-
1980s 
 en.wikipedia.org/wiki/Hepatitis 
Epidemiology and etiology 
Understanding Chronic Hepatitis B  
Mechanisms  
  • The specific mechanism varies and depends on the underlying 
cause for the condition.  
• In viral hepatitis, the presence of the virus in the liver cells causes 
the immune system to attack the liver, resulting in inflammation 
and impaired function. 
• In autoimmune hepatitis, the immune system attacks the liver due 
to the autoimmune disease. 
• In some hepatitis, often including hepatitis caused by alcoholism, 
fat deposits accumulate in the liver, resulting in fatty liver disease 
(steatohepatitis). 
• Chronic hepatitis in severe cases is occurring  with portal based 
inflammation, fibrosis, disruption of the terminal plate, and 
piecemeal necrosis.   
• Chronic hepatitis without piecemeal necrosis (formerly called 
chronic persistent hepatitis) has no significant periportal necrosis or 
regeneration with a fairly dense mononuclear portal infiltrate.  
 en.wikipedia.org/wiki/Hepatitis 
Mechanisms 
Hepatitis A, B, C, D 
 Clinical investigation 
  
• Chronic hepatitis may cause nonspecific symptoms such as malaise, 
tiredness, and weakness, and often leads to no symptoms at all.  
• It is commonly identified on blood tests performed either 
for screening or to evaluate nonspecific symptoms.  
• The presence of jaundice indicates advanced liver damage.  
• On physical examination there may be enlargement of the liver.  
• Extensive damage leads to weight loss, easy bruising and bleeding, 
peripheral edema (swelling of the legs), and accumulation 
of ascites (fluid in the abdomen).  
• Acne, abnormal menstruation, lung scarring, and inflammation of 
the thyroid gland and kidneys may be present in women with 
autoimmune hepatitis. 
• Hepatitis associated aplastic anemia may occur 2–3 months after an 
acute attack of hepatitis. 
• Superinfection and coinfection with HDV results in more severe 
complications compared to infection with HBV alone.  
 
 en.wikipedia.org/wiki/Hepatitis 
 Clinical investigation 
Alcoholic hepatitis 
  
• Alcoholic hepatitis is characterized by a myriad of symptoms, which may 
include feeling unwell, enlargement of the liver, development of fluid in the 
abdomen (ascites), and modest elevation of liver enzyme levels (as 
determined by liver function tests).  
• Alcoholic hepatitis can vary from mild with only liver enzyme elevation to 
severe liver inflammation with development of jaundice, 
prolonged prothrombin time, and even liver failure. Severe cases are 
characterized by either obtundation (dulled consciousness) or the 
combination of elevated bilirubin levels and prolonged prothrombin time; 
the mortality rate in both severe categories is 50% within 30 days of onset. 
• Alcoholic hepatitis is distinct from cirrhosis caused by long-term alcohol 
consumption.  
• Alcoholic hepatitis by itself does not lead to cirrhosis, but cirrhosis is more 
common in patients with long term alcohol consumption.  
• Some alcoholics develop acute hepatitis as an inflammatory reaction to the 
cells affected by fatty change (alcoholic steatonecrosis) . 
• Neuropsychiatric features: asymmetric tremor, clumsiness with the hands, 
personality changes, dystonia, spasticity, rigidity, emotional lability, 
impulsiveness, disinhibition, self-injurious behavior, cognitive. 
https://en.wikipedia.org/wiki/Alcoholic_hepatitis 
 Clinical investigation 
Autoimmune hepatitis 
  • Individuals with autoimmune hepatitis often have no initial 
symptoms and the disease is detected by abnormal liver function 
tests. 
• Common initial symptoms include fatigue or muscle aches or signs of 
acute liver inflammation including fever, jaundice, and right upper 
quadrant abdominal pain, and occasionally systemic symptoms such 
as arthralgias, myalgias, polyserositis and thrombocytopenia.  
• Patients usually present with evidence of moderate to severe 
hepatitis with elevated serum ALT and AST activities in the setting of 
normal to marginally elevated alkaline phosphatase and gamma-
glutamyltranspeptidase activities.  
• The disease may occur in any ethnic group and at any age, but is 
most often diagnosed in patients between age 40 and 50. 
• Though there is a strong female predominance, men are also at risk 
for the disease.  
https://en.wikipedia.org/wiki/Autoimmune_hepatitis 
 Clinical investigation 
Wilson Disease 1  
• The major patterns of hepatic involvement: chronic active hepatitis, 
cirrhosis (the most common initial presentation) and fulminant hepatic 
failure. 
• Neuropsychiatric features: asymmetric tremor, difficulty speaking, excessive 
salivation, ataxia, masklike facies, clumsiness with the hands, personality 
changes, dystonia, spasticity, grand mal seizures, rigidity, flexion 
contractures, emotional lability, impulsiveness, disinhibition, self-injurious 
behavior, cognitive. 
• Musculoskeletal manifestations: osteoarthritis, osteoporosis, osteomalacia, 
rickets, spontaneous fractures. 
• Hematologic and renal manifestations: intravascular hemolysis, urolithiasis, 
hematuria. 
• Kayser-Fleischer rings: the deposition of copper in the Descemet membrane 
in the limbus of the cornea with the color from greenish gold to brown. 
• Skin pigmentation and a bluish discoloration at the base of the fingernails 
(azure lunulae). 
https://en.wikipedia.org/wiki/Autoimmune_hepatitis 
 Clinical investigation 
Wilson Disease 2  
Kayser-Fleischer rings.  
 pbs.twimg.com/media/BWyLrr0IIAEhORa.png 
Skin pigmentation and a bluish 
discoloration at the base of the 
fingernails (azure lunulae). 
 Clinical investigation 
The natural history of chronic hepatitis B virus infection  
• Stage 1: high viral loads and immune tolerance. In acute infection, this 
corresponds to the incubation period, but with neonatal chronic infection, this 
period often lasts for decades. 
• Stage 2: an immunologic response develops leading to hepatocyte necrosis. In 
patients with chronic infection, stage 2 may persist for 10-20 years and lead to 
cirrhosis and its complications.  
• Stage 3: the immune response decreases the number of infected cells with 
beginning of low viral replication, referred to as the inactive carrier state. In this 
stage, HBeAg is no longer detectable, a marked decrease in HBV viral load is 
observed, and aminotransferase levels become normal. Some patients continue 
to have high levels of serum HBV DNA and amino-transferases (referred to as 
HBeAg-negative chronic hepatitis), because of HBV variants that prevent the 
production of HBeAg.  
• Stage 4: patients become negative for HBeAg and positive for anti-HBs, and HBV 
DNA is usually no longer detectable in serum, although still present in liver 
tissue. Immune clearance occurs at a rate of about 1% per year in chronic 
carriers of HBV. Some patients can reactivate their hepatitis B when given 
chemotherapy or immuno-suppressive treatment. Patients with active HBV 
replication are at increased risk for cirrhosis, hepatic decompensation and 
hepatocellular carcinoma compared to inactive carriers.   
journalofclinicalvirology.com/article/S1386-6532(05)80024-1/abstract 
 Clinical investigation 
Activity 
  • Grade 0: No significant inflammation or necrosis. 
• Grade 1 (minimal activity): Portal inflammation with 
predominantly mononuclear cells almost entirely 
confined to the portal areas, no interface hepatitis or 
lobular inflammatory foci. 
• Grade 2 (mild activity): Mild portal inflammation, 
interface hepatitis, and scant lobular spotty necrosis. 
• Grade 3 (moderate activity): Moderate portal 
inflammation, interface hepatitis, and lobular spotty 
necrosis. 
• Grade 4 (severe activity): Marked portal inflammation, 
interface hepatitis, and lobular necrosis, including 
bridging necrosis. 
http://emedicine.medscape.com/article/1610728-overview#a6 
 Clinical investigation 
Fibrosis 
  
Stage 0: No fibrosis 
Stage 1: Fibrous portal expansion 
Stage 2: Periportal fibrous extension 
Stage 3: Fibrous septa formation, including 
portal-to-central bridging fibrosis 
Stage 4: Cirrhosis 
http://emedicine.medscape.com/article/1610728-overview#a6 
 Diagnosis 
  
• Diagnosis is made by assessing an individual's 
symptoms, physical exam, and medical history, in 
conjunction with blood tests, liver biopsy, and imaging.  
• Blood testing includes blood chemistry, liver enzymes, 
serology and nucleic acid testing.  
• Abnormalities in blood chemistry and enzyme results 
may be indicative of certain causes or stages of 
hepatitis. 
• Imaging can identify steatosis of the liver but liver 
biopsy is required to demonstrate fibrosis and cirrhosis. 
• A biopsy is unnecessary if the clinical, laboratory, and 
radiologic data suggests hepatitis.  
 en.wikipedia.org/wiki/Hepatitis 
 Diagnosis 
Special blood testing  
  • Hepatitis B: surface antigen (HBsAg), hepatitis B core antigen (HBcAg),  IgM antibodies specific to the hepatitis B core antigen (anti-HBc IgM), 
hepatitis B e (a viral protein that is secreted by hepatitis B infected cells) antigen 
(HBeAg). The presence of HBeAg in a host's serum is associated with much higher 
rates of viral replication and enhanced infectivity; however, variants of 
the hepatitis B virus do not produce the 'e' antigen, so this rule does not always 
hold true. 
• Hepatitis C: HCV antibody enzyme immunoassay or ELISA, recombinant 
immunoblot assay, and quantitative HCV RNApolymerase chain 
reaction (PCR). HCV RNA can be detected by PCR typically one to two weeks after 
infection, while antibodies can take substantially longer to form and thus be 
detected. 
• Hepatitis D: HDAg in two forms; a large (L)-HDAg, and a small (S)-HDAg of 24kDa. 
HDAg-S is produced in the early stages of an infection and enters the nucleus and 
supports viral replication. HDAg-L, in contrast, is produced during the later stages 
of an infection, acts as an inhibitor of viral replication, and is required for assembly 
of viral particles. 
• Autoimmune hepatitis: antinuclear antibody (ANA), anti-smooth muscle 
antibody (SMA), liver/kidney microsomal antibody (LKM-1, LKM-2, LKM-3), anti 
soluble liver antigen and liver–pancreas antigen (SLA/LP) and anti-mitochondrial 
antibody (AMA)), increased Immunoglobulin G level. The diagnosis always requires 
a liver biopsy. 
 en.wikipedia.org/wiki/Hepatitis_C  en.wikipedia.org/wiki/Hepatitis 
 Diagnosis 
Liver chemistry test 
  
 en.wikipedia.org/wiki/Hepatitis 
Liver chemistry test Clinical implication of abnormality 
Alanine transaminase (ALT) 
Hepatocellular damage  Aspartate transaminase (AST) 
Lactate dehydrogenase 
Bilirubin 
Cholestasis  
Alkaline phosphatase 
Gamma-glutamyl transpeptidase (GGT) 
Bile acids 
Prothrombin time 
Impaired synthetic function  
Albumin (ALB) 
 Diagnosis 
Imaging studies   
The following radiologic 
studies may be used to 
evaluate patients with 
hepatitis B disease: 
• Abdominal 
ultrasonography 
• Abdominal computed 
tomography (CT) scanning 
• Abdominal magnetic 
resonance imaging (MRI). 
 commons.wikimedia.org/wiki/File:Liversteatosis.png emedicine.medscape.com/article/177632-overview 
Echosound of 
parenchyma 
is increased and 
heterogeneous. 
Fatty liver 
disease as seen 
on CT. 
 Diagnosis 
The histopathologic features   
• The histopathologic features of 
chronic hepatitis from any 
cause are very similar and do 
not distinguish one disease 
from another.  
• The portal tracts show variable 
number of mononuclear cells, 
principally small lymphocytes 
with a variable population of 
plasma cells and macrophages.  
• Eosinophils may also be 
present. The inflammation in 
cases with little or no activity 
is largely limited to portal 
tracts. 
pathpedia.com/education/eatlas/histopathology/liver_and_bile_ducts/chronic_hepatitis_c.aspx 
 Diagnosis 
Wilson Disease    
• Serum ceruloplasmin levels are less than 20 mg/dL (reference range, 20-40 
mg/dL) in approximately 90% of all patients.   
• The urinary copper excretion rate is greater than 100 mcg/day (reference 
range, < 40 mcg/day) in most patients.   
• In a patient with Kayser-Fleischer rings, a serum ceruloplasmin level < 0 
mg/dL and 24-hoyr urine copper excretion >40 mcg/day establish the 
diagnosis.   
• Hepatic copper concentration (criterion standard) on a liver biopsy 
specimen is >250 mcg/g of dry weight even in asymptomatic patients. 
• Radiolabeled copper testing directly assays hepatic copper metabolism. 
• Genetic testing is limited to screening of family members for an identified 
mutation detected in the index patient. 
• Brain imaging shows characteristic findings; MRI appears to be more 
sensitive than CT in detecting early lesions.. 
• Resting ECG abnormalities include left ventricular or biventricular 
hypertrophy, early repolarization, ST segment depression, T-wave inversion, 
and various arrhythmias. 
emedicine.medscape.com/article/183456-overview 
Diagnosis 
People With Chronic Hepatitis B Often Do Not 
Know It 
Treatment 
Lifestyle modifications   
  
• Lifestyle modifications are strongly 
recommended for patients with 
chronic hepatitis. 
• Even when efficacious 
pharmacologic interventions are 
identified, lifestyle changes will 
likely represent an adjuvant 
treatment because new drugs are 
inevitably expensive and may have 
unanticipated adverse effects after 
prolonged use.  
• Lifestyle modifications typically 
encompass both dietary 
intervention and physical activity 
goals.  
ncbi.nlm.nih.gov/pmc/articles/PMC3127780/ 
MyPyramid 
Treatment  
Hepatitis B, D 
  
• Patients with persistently elevated serum alanine aminotransferase, and 
HBV DNA levels are candidates for therapy. 
• Treatment lasts from six months to a year, depending on medication and 
genotype. 
• Although none of the available drugs can clear the infection, they can stop 
the virus from replicating, thus minimizing liver damage.  
• There are seven medications licensed for treatment of hepatitis: 
antiviral drugs (lamivudine, adefovir, tenofovir, telbivudine and entecavir, 
and the two immune system modulators interferon alpha-
2a and PEGylated interferon alpha-2a. The World Health Organization 
recommended a combination of tenofovir and entecavir as first line 
agents. 
• Interferon treatment may produce an e antigen seroconversion rate of 
37% in genotype A but only a 6% seroconversion in type D.  
• The drug myrcludex B, which inhibits virus entry into hepatocytes, is in 
clinical trials as of October 2015. 
 en.wikipedia.org/wiki/Myrcludex_Ben.wikipedia.org/wiki/Hepatitis_B 
Treatment  
Hepatitis C  
  
• HCV induces chronic infection in 50–80% of infected 
persons.  
• Approximately 40–80% of these clear with treatment. 
• In rare cases, infection can clear without treatment. 
• Those with chronic hepatitis C are advised to 
avoid alcohol and medications toxic to the liver, and to 
be vaccinated for hepatitis A and hepatitis B. 
• Ultrasound surveillance for hepatocellular carcinoma is 
recommended in those with accompanying cirrhosis. 
 en.wikipedia.org/wiki/Hepatitis_C 
Treatment  
Alcoholic hepatitis 
  
• Clinical practice guidelines by the American College of 
Gastroenterology have recommended corticosteroid 
treatment with prednisolone 40 mg daily for four 
weeks followed by a taper. Prednisolone gave a small 
reduction in mortality at 28 days but this did not reach 
significance, and there were no improvements in 
outcomes at 90 days or 1 year. 
 
• Pentoxifylline (a xanthine derivative) is used to improve 
blood flow  for 4 weeks to prevent one patient from 
dying. Pentoxifylline did not improve survival alone or 
in combination.  
https://en.wikipedia.org/wiki/Alcoholic_hepatitis 
Treatment  
Autoimmune hepatitis 
  
• Treatment may involve the prescription of 
immunosuppressive glucocorticoids, with or 
without azathioprine, and remission can be achieved in up 
to 60–80% of cases, although many will eventually 
experience a relapse. Budesonide has been shown to be 
more effective in inducing remission than prednisone, and 
result in fewer adverse effects. 
• Patients who do not respond to glucocorticoids and 
azathioprine may be given other immunosuppressives like 
mycophenolate, cyclosporin, tacrolimus,methotrexate, etc.  
• Liver transplantation may be required if patients do not 
respond to drug therapy or when patients present with 
fulminant liver failure. 
https://en.wikipedia.org/wiki/Autoimmune_hepatitis 
Treatment  
Wilson Disease  
• The mainstay of therapy is lifelong use of chelating agents 
(e.g., penicillamine, trientine). 
• Symptoms, particularly neurologic ones, may worsen with 
initiation of chelation. 
• Surgical decompression or transjugular intrahepatic 
shunting (TIPS) is reserved for recurrent or uncontrolled 
variceal bleeding unresponsive to standard conservative 
measures. 
• Orthotopic liver transplantation is curative. 
• Other treatments (anticholinergics, baclofen, GABA 
antagonists, levodopa, antiepileptics, neuroleptics ) 
• Protein restriction, lactulose, or both to treat hepatic 
encephalopathy 
emedicine.medscape.com/article/183456-overview 
Treatment 
How to Treat Chronic Hepatitis B  
Prognosis 
 
• Prognosis depends heavily on the disease or 
condition that is causing the symptoms. 
• Chronic damage to the liver can result in the 
formation of scar tissue (fibrosis) and can result 
in nodules that block the liver from functioning 
properly (cirrhosis). 
• Another complication of chronic hepatitis is liver 
cancer, specifically hepatocellular carcinoma.   
• Some cases can require a liver transplant. 
 
 en.wikipedia.org/wiki/Hepatitis 
Prophylaxis 1 
 
• Vaccines are available to prevent hepatitis B.  
• Vaccines to prevent hepatitis B have been available since 
1986 and have been incorporated into at least 177 national 
immunization programs for children.  
• Immunity is achieved in greater than 95% of children and 
young adults receiving the three-dose recombinant virus 
vaccine.  
• Vaccination within 24 hours of birth can prevent 
transmission from an infected mother.  
• Adults over 40 years of age have decreased immune 
response to the vaccine.  
• The vaccine for hepatitis B protects against hepatitis D virus 
because of the latter's dependence on the presence of 
hepatitis B virus for it to replicate.  
 en.wikipedia.org/wiki/Hepatitis 
 Prophylaxis 2 
 
• HBV, HCV transmission can be prevented by screening of donated 
blood, plasma, organ tissue and semen, by viruses inactivation in 
plasma-derived products, by risk-reduction counselling and by 
implementation of infection control practices.  
• For HBV the single most effective prevention measure is routine 
immunization for infants. 
• Immunization should also be offered to high-risk individuals 
including healthcare workers, persons with multiple sex partners, 
intravenous drug users, patients with chronic diseases who are 
likely to undergo multiple percutaneous procedures and contacts of 
HBV-infected persons.  
• Babies born to HBsAg carrier mothers should be protected against 
perinatal transmission by administration of hepatitis B 
immunoglobulin and HBV vaccine. 
ncbi.nlm.nih.gov/pmc/articles/PMC1079522/ 
Clinical cases, 1a 
 Hepatitis C and Alcohol Abuse - What is the Treatment Plan? 
 
A 57-year-old African American male (AAM) with a past medical history (PMH) of 
hepatitis C, alcohol (EtOH) abuse, and hypertension (HTN) is referred to the GI clinic 
because of elevated liver function tests (LFTs). He has no complaints. 
 
Past medical history (PMH) 
Intravenous drug abuse (IVDA) with heroin and cocaine abuse 3o years ago, hepatitis 
C, heavy alcohol abuse, HTN. Rectal bleeding for 2 months - a colonoscopy showed 9 
benign polyps (one tubular adenoma and 8 hyperplastic polyps). 
 
Medications 
Tenormin (atenolol), lisinopril. 
 
Social history (SH) 
Drug abuse as described above. He told his PCP that he is "in remission" from 
alcohol. On closer questioning, the patient admitted to long term alcohol abuse in 
binging sprees, drinking 3-5 bottles of wine whenever he can afford it. The last binge 
was just 2 weeks ago. He finances his EtOH abuse with the money he is receives for 
disability because of his liver disease. 
 
  
clinicalcases.org/2004/03/hepatitis-c-and-etoh-abuse-typical.html 
Clinical cases, 1b 
 Physical examination 
WD/WN in NAD (well-developed, well-nourished, no apparent distress). 
No signs of chronic liver disease. 
HEENT (Head, Eye, Ear, Nose and Throat Exam): no teeth (lost in brawls as per 
patient). 
The rest of the examination was normal. 
 
What is your diagnosis? 
Hepatitis and alcohol abuse. 
 
What laboratory work-up would you order? 
CBC, CMP, AFP (complete blood count, comprehensive metabolic panel, alpha-
fetoprotein). 
Liver ultrasound (U/S). 
 
What about hepatitis C genotype? 
The treatment response in hepatitis C depends on the genotype. The response in 
HCV type 1 is only 40% with interferon (INF) plus ribavirin for 12 months. HCV type 2 
and 3 have a better response rate of 80% after 60 months. The patient's genotype 
was 1a. clinicalcases.org/2004/03/hepatitis-c-and-etoh-abuse-typical.html 
Clinical cases, 1c 
 
Would you recommend antiviral treatment with INF and ribavirin? 
No. EtOH abuse is a contraindication to the antiviral treatment of hepatitis C. 
 
What happened? 
The patient was referred to a drug abuse counseling center and a follow-up (F/U) 
appointment was made in 1 month to monitor the progress. Liver U/S and repeat 
LFT were ordered. All patients with chronic hepatitis C need AFP and liver U/S every 
6 months to screen for hepatocellular CA. 
 
What did we learn from this case? 
Take a careful history of drug abuse. You cannot treat hepatitis C patients if the 
patient is still drinking heavily. EtOH abuse has a detrimental effect on hepatitis C 
liver disease (interestingly, this is not typically the case with hepatitis B). 
Even if you decide to treat this patient, his chance of response would be virtually 
zero because of the genotype and EtOH abuse. The studies show that African 
American patients also have a lower response rate. In conclusion, we should first 
help this patient stop drinking before treating his hepatitis C. 
clinicalcases.org/2004/03/hepatitis-c-and-etoh-abuse-typical.html 
Clinical cases, 2 
 
Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B. 
 
Anti-TNF-α agents have emerged as a potent treatment for patients with 
rheumatoid arthritis unresponsive to conventional disease-modifying antirheumatic 
drugs. Increased susceptibility to infections induced by these drugs is the main 
complication of their use.  
Reactivation of hepatitis B virus (HBV) is one of the most worrisome side effects in 
patients with HBV infection receiving anti-TNF-α.  
Doubrawa E with colleagues from Hospital de Clínicas, Universidade Federal do 
Paraná, Rua Nilo Cairo 36/105, Curitiba, PR, Brazil report the case of a 56-year-old 
male patient with stable hepatitis B and good response to the antiviral combination 
of lamivudine and tenofovir when infliximab was started.  
The patient went into remission.  
During the 30-month treatment with the biologic, his liver function remained stable, 
with no HBV reactivation. 
dgcases.docguide.com/use-infliximab-patient-rheumatoid-arthritis-and-chronic-hepatitis-b 
Clinical cases, 3 
 
Chronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis 
development during interferon alpha therapy. 
 
Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis 
B, C, and D, with immunomodulatory and antiviral activity.  It has been widely 
claimed that interferon alpha triggers autoimmunity, with its broad adverse effect 
profile. Kose S from Education and Research Hospital Department of Infectious 
Diseases and Clinical Microbiology, Izmir, Turkey present the case of a 29-year-old 
male patient with chronic hepatitis B diagnosis who developed type 1 diabetes 
mellitus and autoimmune thyroiditis during treatment with interferon alfa-2b. 
Within four months of initiation of treatment, the patient presented to clinic with 
dry mouth, urinary frequency (8 to 10 times per day), drinking plenty of water, night 
time urination, and tiredness. He was admitted to the clinic when his fasting blood 
glucose level was detected to be high. After examinations, the patient was 
diagnosed with type 1 diabetes and autoimmune thyroiditis and began to receive 
treatment with insulin and propranolol.  
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Clinical cases, 4 
 Successful kidney transplantation from a hepatitis B surface antigen-positive donor 
to an antigen-negative recipient using a novel vaccination regimen. 
 
Transplanting a kidney from a hepatitis B surface antigen (HBsAg)-positive donor to 
an HBsAg-negative recipient who is naturally immune has been successful in 
countries endemic for hepatitis B virus (HBV). However, in most of these cases, the 
donors were deceased. Singh G present a report of a successful HBsAg-discordant 
kidney transplantation in the United States; in this case, a living donor kidney was 
transplanted to a vaccinated recipient. The wife of a 58-year-old HBsAg-negative 
man volunteered to donate a kidney to her husband. She had chronic hepatitis B but 
undetectable HBV DNA. She tested positive for HBsAg and antibody to hepatitis B 
core antigen, but hepatitis B e antigen was undetectable. The recipient failed to 
develop an antibody response to 3 doses of intramuscular recombinant HBV vaccine 
given in consecutive months. Immunity was induced by using biweekly intradermal 
vaccine. However, antibody titer tapered to <10 mIU/mL over 14 months. An 
intramuscular booster vaccine resulted in a prolonged anamnestic response, 
allowing for successful living unrelated donor transplantation. During the 10 years 
since transplantation, the patient has continued to have normal liver function, with 
undetectable HBsAg and HBV DNA.    
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Clinical cases, 5 
 
Telbivudine myopathy in a patient with chronic hepatitis B. 
 
A 25-year-old man with hepatitis B virus (HBV) infection received antiviral treatment 
with telbivudine 600 mg daily. Six months after starting treatment, the patient 
developed progressive weakness and myalgia. Physical examination showed 
symmetrical proximal weakness. Blood tests at admission revealed positive hepatitis 
b surface antigen (HBs Ag), and, elevated creatine kinase (CK) level (1,614 U/L, 
normal range: 38-174 U/L). Aspartate aminotransferase was 64.7 U/L (normal range: 
8-40 U/L), and LDH (lactate dehydrogenase) was 293 U/L (normal range: 80-285 
U/L). Electrodiagnostic studies indicated myopathic changes. A muscle biopsy 
revealed myositis and no mitochondrial changes were found. Drug-induced 
myopathy was suspected and telbivudine was changed to entecavir. The muscle 
weakness and laboratory findings improved. A patient developed drug-induced 
myopathy during long-term treatment with telbivudine for chronic HBV. To promptly 
detect this reversible adverse event, monitoring of serum CK level and recognition of 
myopathic signs and symptoms are necessary. Further investigations are needed to 
clarify the possible mechanism of telbivudine-induced myopathy. 
dgcases.docguide.com/telbivudine-myopathy-patient-chronic-hepatitis-b 
Diagnostic and treatment guidelines 
 
• Treatment of Chronic Hepatitis B: 2015 
• Recommendations for Testing, Managing, and Treating 
Hepatitis: 2014 
• Diagnosis and Management of Autoimmune Hepatitis: 
2014 
• The Diagnosis and Management of Non-Alcoholic Fatty 
Liver Disease: 2012 
• Diagnosis and Treatment of Wilson Disease: An 
Update: 2014 
• Liver Biopsy: 2014 
• Evaluation for Liver Transplantation in Adults: 2013 
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